Biodexa Pharmaceuticals (BDRX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an extension to meet the $1.00 minimum bid price requirement. This development provides the company with additional time to stabilize its stock price, crucial for its continued Nasdaq listing. Investors will be watching closely as Biodexa works towards compliance by the end of October 2024.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
